UCB’s Cimzia wins US OK in psoriatic arthritis
This article was originally published in Scrip
Executive Summary
UCB gained US approval on 30 September to market Cimzia (certolizumab pegol) as a treatment for adults with active psoriatic arthritis (PsA), a chronic inflammatory condition that causes pain, swelling and stiffness in and around the joints and tendons, and usually occurs in combination with psoriasis.